HBV mutation literature information.


  Association of HBsAg mutation patterns with hepatitis B infection outcome: Asymptomatic carriers versus HCC/cirrhotic patients.
 PMID: 31105017       2019       Annals of hepatology
Abstract: A number of truncation-related mutations were higher in HCC/Cirrhotic group (P>0.001), albeit only C69* stop codon was statistically significant (P=0.003).
Abstract: CONCLUSION: The higher frequency of substitutions in MHR and immune epitopes at positions such as Y134 and P120 as well as stop codons such as C69* in HCC/cirrhotic group might candidate them as predictive factors for infection outcome.
Abstract: However, Y134N/F/L (P=0.04) and P120T/S (P=0.009) were significantly detected in MHR and B-cell epitope of HCC/ PMID: 31130119       2019       Mikrobiyoloji bulteni
Abstract: Because of the HBV pol/S gene overlapping, in 27 patients immun-selected amino acid substitutions (sI110L, sT127P, sS114A, sT123A), in nine patients HBIg selected escape mutants (sP120R, sT123N, sE164D, sY134F, sQ129H, sT118A,


  [Determination of reverse transcriptase inhibitor nucleoside analogue resistance profile in pretreatment phase of patients with viral hepatitis B].
 PMID: 31130120       2019       Mikrobiyoloji bulteni
Abstract: However, potential drug resistance mutations such as rtR164R, rtG165D/A, rtG172Q, rtS176N, rtF178V, rtA181G, rtS185N/G/C, rtV207M, rtQ215H/S, rtL231V, rtI233K, rt


  Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection.
 PMID: 31147594       2019       Scientific reports
Abstract: Notably, 11 mutations at position 169, 202, 250, 173, 180, 200, 207, 214, 237, 242 and 245 coexisted with M204I or V.
Table:
Table: A181T/V
Table: A200V


  Hepatitis B virus reverse transcriptase polymorphisms between treated and treatment-naive chronically infected patients.
 PMID: 31179360       2019       Virusdisease
Abstract: 13/98 (13.27%) of patients had M539I/V substitutions corresponding to YMDD motif.
Abstract: Drug resistance conferring substitutions (DRCSs) were rtL180M (22/98), rtA194V (11/98), rtM204V (1/98), and rtM204I (11/98).
Abstract: Two substitutions N459Y and L515M were significantly correlated (R2 = 0.486 and R2 = 0.941 respectively) with FLLAQ motif variation.


  Characterization and Clinical Significance of Natural Variability in Hepatitis B Virus Reverse Transcriptase in Treatment-Naive Chinese Patients by Sanger Sequencing and Next-Generation Sequencing.
 PMID: 31189581       2019       Journal of clinical microbiology
Abstract: Primary or secondary NA resistance (NAr) mutations were not found, except A181T in RT (rtA181T) by Sanger sequencing, but they were detected by next-generation sequencing.
Introduction: For instance, I195M in the S protein (sI195M) and sW196S can produce rtM204I and rtL180M/rtM204I in RT, which could confer resistance to LMV.
Introduction: For instance,


  Complementation of Wild-Type and Drug-Resistant Hepatitis B Virus Genomes to Maintain Viral Replication and Rescue Virion Production under Nucleos(t)ide Analogs.
 PMID: 31218588       2019       Virologica Sinica
Abstract: In the present study, HBV genomes with frequently detected reverse transcriptase (RT)/surface truncation MTs, rtA181T/sW172*, rtV191I/sW182* and rtM204I/sW196*, were phenotypically characterized alone or together with their WT counterparts in different ratios by transient transfection in the absence or presence of NAs.


  Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis.
 PMID: 31248149       2019       Viruses
Abstract: None of the known tenofovir resistance mutations (M240V/I, L180M, A194T, V214A, N238T) were identified in any individuals.
Result: Although the frequency of amino acid substitutions were not significantly different, a total of 16 amino acid substitutions in the polymerase domain occurred only in tenofovir-experienced isolates compared to tenofovir-naive isolates, including S117Y, S117C, I121N, T128I, M129L, R138K, R138E, L140P, V142A,


  Recombinant HBsAg of the Wild-Type and the G145R Escape Mutant, included in the New Multivalent Vaccine against Hepatitis B Virus, Dramatically Differ in their Effects on Leukocytes from Healthy Donors In Vitro.
 PMID: 31249567       2019       Frontiers in microbiology
Discussion: As mentioned above, some of our results were different from other studies, such as the influence of sC69* on viral replication.
Discussion: As shown in our previous report, the sC69* mutant had impaired replication and secretion.
Discussion: However, sC69* could inhibit some immune factors expression (RIG-I, IL29, and ISG15) with or without WT.
Discussion: However, in a recent study, reported that sC69* in genotype A HBV had a higher viral replication.


  Impact of hepatitis B virus genotype F on in vitro diagnosis: detection efficiency of HBsAg from Amerindian subgenotypes F1b and F4.
 PMID: 31267215       2019       Archives of virology
Abstract: A phosphorylation site (target for protein kinase C) produced by the G145R substitution might prevent recognition by anti-HBs antibodies.
Abstract: Prediction of the tertiary structure of subgenotypes F1b and F4 revealed changes inside and outside the major hydrophilic region (aa 101-160) of the HBsAg compared to genotype A and the G145R variant.
Abstract: This study examined the effect of virus-like particles containing HBsAg from genotypes A and F (particularly, F1b and F4) produced in Pichia pastoris in relation to the anti-HBs antibodies used in the immunoassays for in vitro diagnosis and compared it with that exerted by the G145R S-escape mutant.



Browser Board

 Co-occurred Entities




   Filtrator